Hemoporfin

Drug Profile

Hemoporfin

Alternative Names: FMD; FuMeiDa; Hematoporphyrin monomethyl ether; HMME -Shanghai Fudan-Zhangjiang Bio-Pharmaceutical

Latest Information Update: 14 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  • Class Hematoporphyrins
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Nevus

Most Recent Events

  • 05 Dec 2016 Launched for Nevus in China (IV)
  • 31 Oct 2016 Registered for Nevus in China (IV)
  • 01 Sep 2008 Phase-III clinical trials in Nevus in China (IV) (ChiCTR-TRC-08000213)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top